Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 7fludarabine 6Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6ruxolitinib 5fludarabine phosphate 5Melphalan 5venetoclax 4Peripheral Blood Stem Cell Transplantation 4itacitinib 3Specimen Handling 3Sirolimus 3Granulocyte Colony-Stimulating Factor 3Cytarabine 3Biopsy 3Azacitidine 3navitoclax 2luspatercept 2Etoposide 2Daunorubicin 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1selinexor 1quizartinib 1pomalidomide 1plerixafor 1pevonedistat 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myeloproliferative Disorders × parsaclisib × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡